Last reviewed · How we verify
NCT06103539
Pacertool Early Feasibility Study - Safety and Performance
trial testing Cardiac catheterization and evoked response to cardiac stimulation in Heart Failure With Reduced Ejection Fraction in 50 participants. Status unknown.
1 September 2024
Quick facts
| Lead sponsor | Pacertool AS |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 December 2023 |
| Primary completion | 1 September 2024 |
| Estimated completion | 30 December 2024 |
| Sites | 1 location across Georgia |
Drugs / interventions tested
- Cardiac catheterization and evoked response to cardiac stimulation
Conditions studied
- Heart Failure With Reduced Ejection Fraction — all drugs for Heart Failure With Reduced Ejection Fraction →
- Dyssynchrony — all drugs for Dyssynchrony →
- Medical Device Performance — all drugs for Medical Device Performance →
Sponsor
Pacertool AS
Who can join
Adults 18 to 80, any sex, with Heart Failure With Reduced Ejection Fraction or Dyssynchrony. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is a non-randomized, two-part, open label, prospective single-site, single arm, safety and performance study. The study is designed to collect acute and long-term clinical data and user reported outcome data from using the PreSens-Catheter and PACER Software during cardiac catheterization and Cardiac Resynchronization Therapy (CRT) device implantation procedures. Subjects with indication for arterial catheterization and CRT will be included.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06103539
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure With Reduced Ejection Fraction
Currently open trials in the same condition.
- NCT07465653 — A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction · Phase 1 · recruiting
- NCT07465679 — A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treat · active not recruiting
- NCT07275931 — Digital Support Program for Patients With Heart Failure - a Cluster-Randomized Hybrid Type 2 Study · NA · recruiting
- NCT06942221 — Digital Solutions in Heart Therapy (DIGNITY) · NA · recruiting
- NCT07087613 — Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06103539 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pacertool AS
- Last refreshed: 26 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06103539.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing